KR890010562A - Active RNase L as a Marker of Virus Infection - Google Patents

Active RNase L as a Marker of Virus Infection Download PDF

Info

Publication number
KR890010562A
KR890010562A KR1019880002189A KR880002189A KR890010562A KR 890010562 A KR890010562 A KR 890010562A KR 1019880002189 A KR1019880002189 A KR 1019880002189A KR 880002189 A KR880002189 A KR 880002189A KR 890010562 A KR890010562 A KR 890010562A
Authority
KR
South Korea
Prior art keywords
hiv
rnase
inhibitor
derna
virus
Prior art date
Application number
KR1019880002189A
Other languages
Korean (ko)
Inventor
에이. 카터 윌리암
Original Assignee
원본미기재
헴 리서어취 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 헴 리서어취 인코오포레이티드 filed Critical 원본미기재
Publication of KR890010562A publication Critical patent/KR890010562A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

내용 없음No content

Description

비루스 감염의 표지 물질로서의 활성 RN 아제 LActive RNase L as a Marker of Virus Infection

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 리보소말 RNA 분해분석에 의해 결정된 것으로서 LAS, ARC 또는 AIDS를 앓고 있는 인간의 PBMC추출물로 부터 추출된 2-5A로 RN 아제 L을 활성화시킴으로서 나타난 폴리아크릴아미드 겔의 전기영동 플레이트 포토그래프이며,1 is an electrophoretic plate photograph of a polyacrylamide gel, as determined by ribosomal RNA digestion assay, shown by activating RNase L with 2-5A extracted from human PBMC extracts suffering from LAS, ARC or AIDS. ,

제2도는 리보소말 RNA 분해분석에 의해 결정된 것으로서 RBMC 추출물에서 RN 아제 L레벨을 활성화시켜 나타난 겔 전기영동 플레이트 프로그래프이다.FIG. 2 is a gel electrophoretic plate program shown by activating RNase L levels in RBMC extracts as determined by ribosomal RNA digestion assays.

Claims (10)

동물의 세포 추출물에서 HIV에 의해 유발되는 유전적 정보 또는 HIV존재를 나타내는 표지물인 RN 아제 L억제제 존재를 결정하는 것을 포함하여 실질적으로 유사한 임상적 상태를 일으키는 일체의 면역 결핍 비루스 또는 다른 비루스 존재를 측정하는 방법.Determining the presence of any immunodeficiency virus or other virus that causes a substantially similar clinical condition, including determining the presence of RNase L inhibitors, genetic information caused by HIV or markers indicating the presence of HIV in animal cell extracts. How to. 인체 생물학적 유체 또는 세포에서 RN 아제 L억제제 존재를 검출하는 것을 포함하여 제1항의 인간의 생물학적 유체 또는 세포에서 숨어있는 인체 면역결핍 비루스존재를 측정하는 방법.A method of measuring human immunodeficiency virus presence hiding in a human biological fluid or cell of claim 1 comprising detecting the presence of an RNase L inhibitor in the human biological fluid or cell. 제2항에 있어서, 생물학적 유체는 혈액 또는 혈액분취물인 것을 특징으로 하는 방법.The method of claim 2, wherein the biological fluid is blood or blood aliquots. 동물조직 추출물을 검사하고 제1항의 적어도 하나의 RN 아제 L억제제 존재 도는 이것의 부재를 측정하는 것을 포함하며, 측정시에 양성을 띤다는 것은 HIV 비루스가 존재함을 나타내는 것을 의미함을 특징으로 하여 동물에 있어서, HIV병을 측정하는 진단테스트.Inspecting animal tissue extracts and determining the presence or absence of at least one RNase L inhibitor of claim 1, wherein being positive at the time of measurement means indicating the presence of HIV viruses Diagnostic tests for measuring HIV disease in animals. 환자의 세포 추출물에서 적어도 하나의 RN 아제 L억제제 존재 또는 부재를 측정하고 RN 아제 L억제제가 검출된다면 유사한 생화학적 상태 또는 임상적 상태를 일으키는 비루스 또는 HIV를 유발시킨 상태의 RN 아제 L억제제 양을 감소시키기에 충분히 dsRNA를 투여하고, 환자의 임상적 증상이 좋아지거나 또는 안정될때까지 deRNA를 계속 투여하는 단계로 구성되어 HIV 또는 이와 유사한 생화학적 상태 또는 임상적 상태를 일으키는 비루스로부터 얻은 병의 회복 정도를 측정하는 방법.Determining the presence or absence of at least one RNase L inhibitor in a cell extract of a patient and if an RNase L inhibitor is detected, reducing the amount of RNase L inhibitor in a viral or HIV induced state that causes a similar biochemical or clinical condition. Administering the dsRNA enough to make it more effective and continuing the administration of the deRNA until the patient's clinical symptoms improve or stabilize, resulting in a recovery of disease from viruses that cause HIV or similar biochemical or clinical conditions. How to measure. 제1항 또는 제5항에 있어서, deRNA는 잘못짝지워진 deRNA인 것을 특징으로 하는 방법.6. The method of claim 1 or 5, wherein the deRNA is mispaired deRNA. 제6항에 있어서, deRNA는 1-5내지 1-30 우라실 또는 구아니딘 염기를 함유하는 폴리이노시네이트 및 폴리시티딜 레이트 복합체인 것을 특징으로 하는 방법.7. The method of claim 6, wherein the deRNA is a polyinosinate and polycytilate complex containing 1-5 to 1-30 uracil or guanidine bases. 제7항에 있어서, deRNA는 일반식(rIn.(C12U)n인 것을 특징으로 하는 방법.8. The method of claim 7, wherein the deRNA is of the general formula (rI n . (C 12 U) n . 동물에 대한 항원으로서 2'-5' A/RN 아제 L경로중에 생화학적 중간물질의 억제제를 유발하는 비루스 또는 RN 아제 L의 HIV 특이 억제제를 투여하는 것을 포함하여 HIV에 대한 면역을 생기게 하는 방법.A method of immunizing HIV, comprising administering an HIV-specific inhibitor of virus or RNase L that induces an inhibitor of a biochemical intermediate in the 2'-5 'A / RNase L pathway as an antigen against an animal. 2'-5' A/RN 아제 L경로에서 생화학적 중간물질의 비루스가 유발한 억제제 또는 RN 아제 L의 HIV 특이 억제제를 -제거하는 효과적인 성분을 HIV 감염동물에 투여하고 억제제가 실질적으로 변형될때까지 계속 투여하는 HIV를 치료하는 방법.In a 2'-5 'A / RNase L pathway, an effective ingredient that removes the biochemical intermediate virus-induced inhibitor or the HIV specific inhibitor of RNase L is administered to the HIV infected animal until the inhibitor is substantially modified. How to treat HIV for continued administration. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019880002189A 1987-12-23 1988-03-03 Active RNase L as a Marker of Virus Infection KR890010562A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13697887A 1987-12-23 1987-12-23
US136978 2002-04-30

Publications (1)

Publication Number Publication Date
KR890010562A true KR890010562A (en) 1989-08-09

Family

ID=22475294

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002189A KR890010562A (en) 1987-12-23 1988-03-03 Active RNase L as a Marker of Virus Infection

Country Status (17)

Country Link
EP (1) EP0325018A3 (en)
JP (1) JP2690493B2 (en)
KR (1) KR890010562A (en)
CN (1) CN1043569A (en)
AU (2) AU1256488A (en)
CA (1) CA1337277C (en)
DK (1) DK112988A (en)
FI (1) FI880960A (en)
HU (1) HU205460B (en)
IL (1) IL85577A0 (en)
NO (1) NO880935L (en)
OA (1) OA08815A (en)
PH (1) PH25365A (en)
PT (1) PT86880B (en)
RU (1) RU1836101C (en)
SU (1) SU1687035A3 (en)
ZA (1) ZA881470B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278042A (en) * 1989-02-06 1994-01-11 The United States Of America As Represented By The Department Of Health & Human Services Method for detecting inhibitors of tat protein
FR2725214A1 (en) * 1994-09-30 1996-04-05 Inst Nat Sante Rech Med NOVEL COMPOUNDS FOR PREPARING ANTI-INFECTIOUS AGENTS
US5985565A (en) 1996-10-09 1999-11-16 Temple University-Of The Commonwealth System Of Higher Education Chronic fatigue syndrome diagnosis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CZ295108B6 (en) 1998-03-20 2005-05-18 Benitec Australia Ltd Synthetic gene comprising dispersed or foreign deoxyribonucleic molecule and a gene construct containing such a synthetic gene
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6207366B1 (en) 1999-04-14 2001-03-27 Temple University- Of The Commonwealth System Of Higher Education Chronic fatigue syndrome diagnosis
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
CN112088903A (en) * 2020-09-28 2020-12-18 武汉愔紫生物科技有限公司 Application of macromolecular protein in antibacterial and antiviral disinfectant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505845A1 (en) * 1981-05-13 1982-11-19 Choay Sa Substrate system for oligo-adenylate synthetase assay - used to diagnose infection and measure interferon concn.
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
EP0325018A2 (en) 1989-07-26
RU1836101C (en) 1993-08-23
CN1043569A (en) 1990-07-04
CA1337277C (en) 1995-10-10
DK112988D0 (en) 1988-03-02
SU1687035A3 (en) 1991-10-23
PH25365A (en) 1991-05-13
AU1256488A (en) 1989-06-29
EP0325018A3 (en) 1990-01-17
FI880960A (en) 1989-06-24
IL85577A0 (en) 1988-08-31
NO880935D0 (en) 1988-03-02
AU660973B2 (en) 1995-07-13
NO880935L (en) 1989-06-26
PT86880A (en) 1988-04-01
DK112988A (en) 1989-06-24
OA08815A (en) 1989-03-31
FI880960A0 (en) 1988-03-02
PT86880B (en) 1993-01-29
JP2690493B2 (en) 1997-12-10
ZA881470B (en) 1988-11-18
HUT47745A (en) 1989-03-28
JPH01171500A (en) 1989-07-06
HU205460B (en) 1992-04-28
AU1618792A (en) 1992-09-10

Similar Documents

Publication Publication Date Title
Bonacini et al. Patients co‐infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA
Ratzan Viral meningitis
Faraoni et al. Evaluation of a rapid antigen and antibody combination test in acute HIV infection
KR890010562A (en) Active RNase L as a Marker of Virus Infection
Pasquier et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV‐1) and HCV
Mendoza et al. COVID-19 in a patient with end-stage renal disease on chronic in-center hemodialysis after evidence of SARS-CoV-2 IgG antibodies. Reinfection or inaccuracy of antibody testing
Fanning et al. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study
Healey et al. Acute hepatitis C infection after sexual exposure.
BR9804648A (en) Monitoring of patient compliance with treatment and bioavailability of drugs by deproteinization of body fluids.
Fabris et al. High prevalence of HCV-RNA in the saliva cell fraction of patients with chronic hepatitis C but no evidence of HCV transmission among sexual partners
EP1563308A4 (en) Methods and kits for diagnosing tumorigenicity
KR880011593A (en) Active RNase L as Marker of Virus Infection
CN104846116A (en) PCR primer groups and probe used for detecting human immunodeficiency virus type I, kit containing PCR primer groups and probe, and detection method
Keiserman et al. Intrafamilial transmission of hepatitis C virus in patients with hepatitis C and human immunodeficiency virus coinfection
Sacks Improving the management of genital herpes
Jehuda-Cohen The HIV seronegative Window period: diagnostic challenges and solutions
WO2014175827A1 (en) Diagnostic kit for rapidly diagnosing a dengue virus, a method of preparing the diagnostic kit and a method of rapidly diagnosing a dengue virus using the diagnostic kit
SULKIN et al. The Frei Test for Lymphogranuloma Venereum: Experiences with a New Antigen (Lygranum) Prepared from Infected Yolk Sac of Developing Chick Embryo
Psomas Of HIV and men
MacDougall Redefining the role of HIV viral load monitoring
Utu-Baku Effect of therapeutic and toxic doses of ivermectin (Mectizan) on total serum proteins and hepatic enzymes of wistar albino rats
Trivedi Newly diagnosed hepatitis C: Lack of symptoms doesn't mean lack of progression
Toyohama et al. Kaposi's sarcoma in a human immunodeficiency virus-negative patient treated with corticosteroid for idiopathic thrombocytopenic purpura
Ercoli Studies on the therapeutic resistance of cutaneous leishmania infections
Leggat et al. Could it be lymphatic filariasis?

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application